The stock of PRA Health Sciences Inc (NASDAQ:PRAH) hit a new 52-week high and has $76.10 target or 35.00% above today’s $56.37 share price. The 7 months bullish chart indicates low risk for the $3.51B company. The 1-year high was reported on Oct, 3 by Barchart.com. If the $76.10 price target is reached, the company will be worth $1.23B more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 145,762 shares traded hands. PRA Health Sciences Inc (NASDAQ:PRAH) has risen 30.90% since February 29, 2016 and is uptrending. It has outperformed by 18.69% the S&P500.
Analysts await PRA Health Sciences Inc (NASDAQ:PRAH) to report earnings on November, 7. They expect $0.62 EPS, up 24.00% or $0.12 from last year’s $0.5 per share. PRAH’s profit will be $38.61 million for 22.73 P/E if the $0.62 EPS becomes a reality. After $0.61 actual EPS reported by PRA Health Sciences Inc for the previous quarter, Wall Street now forecasts 1.64% EPS growth.
PRA Health Sciences Inc (NASDAQ:PRAH) Ratings Coverage
Out of 9 analysts covering PRA Health Sciences (NASDAQ:PRAH), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. PRA Health Sciences has been the topic of 13 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by SunTrust given on Thursday, November 19. The stock has “Buy” rating given by Citigroup on Wednesday, May 4. The stock of PRA Health Sciences Inc (NASDAQ:PRAH) earned “Neutral” rating by UBS on Tuesday, September 6. Citigroup maintained PRA Health Sciences Inc (NASDAQ:PRAH) on Thursday, September 22 with “Buy” rating. The stock of PRA Health Sciences Inc (NASDAQ:PRAH) has “Overweight” rating given on Monday, June 13 by KeyBanc Capital Markets. The rating was initiated by Suntrust Robinson with “Neutral” on Thursday, November 19. The stock of PRA Health Sciences Inc (NASDAQ:PRAH) has “Equal-Weight” rating given on Tuesday, June 21 by First Analysis. As per Tuesday, June 21, the company rating was initiated by Credit Suisse. Credit Suisse reinitiated PRA Health Sciences Inc (NASDAQ:PRAH) on Friday, August 14 with “Outperform” rating. On Monday, March 28 the stock rating was upgraded by SunTrust to “Buy”.
According to Zacks Investment Research, “PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology and psychiatry, oncology and hematology, rare diseases, and respiratory needs. The Company engages in bioanalytical laboratory, clinical pharmacology, clinical development, strategic solutions, post marketing research, clinical informatics, clinical diagnostics, and safety and risk management activities. PRA Health Sciences, Inc. is based in Raleigh, North Carolina.”
More notable recent PRA Health Sciences Inc (NASDAQ:PRAH) news were published by: Businesswire.com which released: “Takeda and PRA Health Sciences Announce Transformational Clinical Development …” on September 12, 2016, also Globenewswire.com with their article: “PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2015 Results …” published on February 24, 2016, Nasdaq.com published: “PRA Health Sciences, Inc. Reports Second Quarter 2016 Results” on July 28, 2016. More interesting news about PRA Health Sciences Inc (NASDAQ:PRAH) were released by: Globenewswire.com and their article: “PRA Health Sciences, Inc. Reports First Quarter 2016 Results and Updates 2016 …” published on April 27, 2016 as well as Globenewswire.com‘s news article titled: “PRA Health Sciences Named Clinical Research Company of the Year” with publication date: April 18, 2016.
PRAH Company Profile
PRA Health Sciences, Inc., incorporated on June 21 2013, is a contract research organization (CRO). The Firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Firm offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company’s integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The Firm provides its clients with clinical development service offerings, which includes both traditional, project Phase I through Phase IV services, as well as embedded and functional outsourcing services. The Company’s clinical development platform includes over 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.